Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STP122G
- Development stage
- Unknown
- Lead developer
- Sirnaomics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
STP122G is a GalNAc-conjugated small interfering RNA (siRNA) therapeutic developed by Sirnaomics for the prevention and treatment of thromboembolic disorders. It utilizes the proprietary GalAhead™ platform technology, specifically mxRNA (miniaturized RNAi triggers), to target and silence the expression of Factor XI (FXI) in the liver. By inhibiting the production of FXI, a key enzyme in the intrinsic coagulation pathway, STP122G aims to provide effective anticoagulation with a significantly reduced risk of bleeding compared to traditional anticoagulants. The drug is administered subcutaneously and is currently being evaluated in Phase I clinical trials to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers.
- Other names
- FXI-GalNAc-siRNA
02
Targets
F11 (Coagulation Factor XI)
Beyond the preview
Go deeper on STP122G.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STP122G.